echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Medical News > Latest Medical News > Innovent's Class 1 new drug IBI112 starts Phase I clinical trial

    Innovent's Class 1 new drug IBI112 starts Phase I clinical trial

    • Last Update: 2020-09-04
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com
    The main purpose of the study was to evaluate the safety and tolerance of Chinese health subjects after a single dose of off-the-cortective injection or intravenous injection of IBI112.
    secondary purpose was to evaluate the characteristics and immunogenicity of post-drug pharmacological dynamics (PK) of IBI112 in a single dose of subderfic injection or intravenous giving to healthy subjects in China.
    purpose of the study was to evaluate the post-IBI112 pharmacodynamic (PD) characteristics of single-dose subderfect injections or intravenous giving to healthy subjects in China.
    IBI112 is an IL-23 monoantigen, IL-23 is a new type of isogenic cytokine consisting of IL-12/IL-23p40 and specific IL-23p19 sub-base.
    -23 play an important role in autoimmune diseases, rheumatoid arthritis and inflammatory bowel diseases and infections.
    .
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.